Recruiting

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

ClinicalTrials.gov IDNCT07469709

PhaseNot Applicable

Enrollment850

SponsorFondazione del Piemonte per l'Oncologia

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Breast Cancer, Colo-rectal Cancer, Ovarian Cancer, Melanoma (Skin Cancer), Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)

About this study

The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase. The PRO-ACTIVE study includes the following activities: * WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors * WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences * WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors * WP4: Study of the tumor microenvironment for recurrence prediction

Primary outcomes

Number, frequency and type of genetic variants in known genes not detected by routine diagnostic tests for hereditary tumours (From enrollment to the last clinical follow-up at month 12)

Eligibility information

Inclusion Criteria: * Age \>18 years; * Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer; * Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion; * Patients with ovarian carcinomas; * Patients with metastatic melanoma; * Patients with stage IIB and IIIA non-small cell lung cancer. Exclusion Criteria: * Age \<18 years; * Unwillingness or inability to give informed consent

Study locations

Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo, Candiolo, Turin 10060 Italy

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.